Edition:
United States

Mithra Pharmaceuticals SA (MITRA.BR)

MITRA.BR on Brussels Stock Exchange

35.80EUR
16 Jul 2018
Change (% chg)

-- (--)
Prev Close
€35.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
122,918
52-wk High
€39.35
52-wk Low
€8.80

Select another date:

Thu, May 3 2018

BRIEF-Mithra Announces Last Subject Visit In Estelle Phase III Study In EU/Russia

* MITHRA ANNOUNCES LAST SUBJECT VISIT IN ESTELLE® PHASE III STUDY IN EU/RUSSIA AND COMPLETION OF ENDOMETRIAL SUBSTUDY

BRIEF-Mithra Pharmaceuticals Announces Positive Donesta Phase IIb Study

* ANNOUNCES POSITIVE DONESTA PHASE IIB STUDY ACHIEVING PRIMARY OBJECTIVE AND CONFIRMING PROMISING SAFETY PROFILE

BRIEF-Mithra Pharmaceuticals Signs Principle Agreement For Estelle Commercialization In Canada With Searchlight Pharma

* SIGNS PRINCIPLE AGREEMENT FOR ESTELLE COMMERCIALIZATION IN CANADA WITH SEARCHLIGHT PHARMA

BRIEF-Mithra Pharmaceuticals Applies For Additional Estelle® Patent Based On Positive Hemostasis Data

* MITHRA APPLIES FOR ADDITIONAL ESTELLE® PATENT BASED ON POSITIVE HEMOSTASIS DATA

BRIEF-Mithra Pharmaceuticals And Mayne Pharma's Vaginal Contraceptive Ring Accepted For Filing By FDA​

* ‍MITHRA AND MAYNE PHARMA'S VAGINAL CONTRACEPTIVE RING ACCEPTED FOR FILING BY FDA​

BRIEF-Mithra And Alvogen Sign LSA For Vaginal Contraception Ring In Russia

* MITHRA AND ALVOGEN SIGN LSA FOR VAGINAL CONTRACEPTION RING IN RUSSIA

BRIEF-Mithra Analysis Across A Range Of Parameters Points To Limited Hemostatic Impact For Estelle

* ANALYSIS ACROSS A RANGE OF PARAMETERS POINTS TO LIMITED HEMOSTATIC IMPACT FOR ESTELLE®,

BRIEF-Mithra Announces Very Promising Hemostasis Results For Estelle​

* ‍MITHRA PHARMACEUTICALS SA - MITHRA ANNOUNCES VERY PROMISING HEMOSTASIS RESULTS FOR ESTELLE®​

BRIEF-Mithra Pharmaceuticals Announces Last Subject Completes Donesta Phase II Study​

* ‍MITHRA ANNOUNCES LAST SUBJECT COMPLETES DONESTA® PHASE II STUDY​

Select another date: